Matsuno H, Kang YM, Okada M, Lee SI, et al. Comparison of the efficacy and safety of LBAL, a candidate adalimumab biosimilar, and adalimumab reference product in patients with active rheumatoid arthritis inadequately responding to methotrexate: a 52-week phase III randomised study. Clin Exp Rheumatol 2021 Jul 7. pii: 16868.
PMID: 34251303